Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Malignant ascites

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    127 result(s) found for: Malignant ascites. Displaying page 5 of 7.
    « Previous 1  2  3  4  5  6  7  Next»
    EudraCT Number: 2011-001230-42 Sponsor Protocol Number: CTKI258A2210 Start Date*: 2012-03-15
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, randomized, double blind, placebo controlled, phase II trial evaluating the safety and efficacy of TKI258 combined with fulvestrant, in postmenopausal patients with HER2- and HR+ bre...
    Medical condition: Breast cancer, HER2 negative and HR positive, with evidence of disease progression after prior endocrine therapy
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: AT (Completed) ES (Completed) HU (Completed) BE (Completed) IT (Completed) NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-002468-18 Sponsor Protocol Number: EZH-102 Start Date*: 2016-02-19
    Sponsor Name:Epizyme, Inc.
    Full Title: A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects with Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
    Medical condition: Atypical teratoid rhabdoid tumor (ATRT), Malignant rhabdoid tumor (MRT), Rhabdoid tumor of kidney (RTK), selected tumors with rhabdoid features. Epithelioid sarcoma, Epithelioid malignant peripher...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064886 Renal medullary carcinoma LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065870 Atypical teratoid/rhabdoid tumor of CNS LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073134 Extraskeletal myxoid chondrosarcoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073335 Rhabdoid tumor LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074121 Rhabdoid tumor of the kidney LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042863 Synovial sarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015100 Epithelioid sarcomas HLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed) DE (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-023135-42 Sponsor Protocol Number: VIT-0910 Start Date*: 2016-07-05
    Sponsor Name:Centre Oscar Lambret
    Full Title: INTERNATIONAL RANDOMIZED PHASE II TRIAL OF THE COMBINATION OF VINCRISTINE AND IRINOTECAN WITH OR WITHOUT TEMOZOLOMIDE (VI OR VIT) IN CHILDREN AND ADULTS WITH REFRACTORY OR RELAPSED RHABDOMYOSARCOMA
    Medical condition: Recurrent or refractory rhabdomyosarcoma
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039027 Rhabdomyosarcoma recurrent PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed) NL (Ongoing) ES (Ongoing) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-005241-45 Sponsor Protocol Number: MK3475-061 Start Date*: 2015-04-22
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel in Subjects with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma who Progressed after Fi...
    Medical condition: Gastric or Gastroesophageal Junction Adenocarcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) IT (Completed) EE (Completed) ES (Completed) IE (Completed) DE (Completed) GB (GB - no longer in EU/EEA) DK (Completed) BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-002917-30 Sponsor Protocol Number: CARCINOSIS Start Date*: 2015-09-10
    Sponsor Name:Medical University of Vienna
    Full Title: Assessment of histopathological response to combination chemotherapy with Oxaliplatin, Irinotecan, Fluorouracil and Bevacizumab in patients with peritoneal metastasis from colorectal cancer (CARCIN...
    Medical condition: Patients with peritoneal carcinomatosis from colorectal cancer are treated with a combination chemotherapy (FOLFOXIRI+ Bevacizumab)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    20.0 100000016861 10034672 Peritoneal metastases LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-005286-41 Sponsor Protocol Number: CF102-301HCC Start Date*: 2022-12-08
    Sponsor Name:CanFite BioPharma Ltd.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients with Child-Pugh Class B7 Ci...
    Medical condition: Advanced Hepatocellular Carcinoma in Patients with Child-Pugh Class B7 Cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Trial now transitioned) PL (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-005181-20 Sponsor Protocol Number: CEPO906A2303 Start Date*: 2006-05-19
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, parallel group, open-label, active controlled, multicenter Phase III trial of Patupilone (EPO906) versus pegylated liposomal doxorubicin (Doxil/Caelyx) in taxane/platinum refractory/r...
    Medical condition: Approximately 75% of women with ovarian cancer present advanced disease. Survival is highly dependent on the stage of disease at the initiation of treatment. Favorable prognostic factors include yo...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) ES (Completed) FI (Completed) DK (Completed) HU (Completed) GR (Completed) IT (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2011-005194-23 Sponsor Protocol Number: D0102C00006 Start Date*: 2012-11-19
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase IIa Multi-centre Randomised Double-Blind Placebo-controlled Study to Assess the Efficacy, Safety and Pharmacokinetics of AZD8931 in Combination with Paclitaxel versus Paclitaxel alone in Pa...
    Medical condition: Metastatic, Gastric or Gastro-oesophageal Junction Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071114 Metastatic gastric adenocarcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-000260-14 Sponsor Protocol Number: UC-0140/1901 Start Date*: 2020-01-30
    Sponsor Name:UNICANCER
    Full Title: Open-label, randomized, multicenter, phase III study, comparing standard chemotherapy to standard combination of endocrine therapy with Abemaciclib as initial Metastatic treatment among patients wi...
    Medical condition: Untreated metastatic Estrogen Receptor positive (ER+), Human Epidermal Growth Factor Receptor-2 negative (HER2-) breast cancer with visceral involvement.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-005157-23 Sponsor Protocol Number: DART Start Date*: 2013-05-21
    Sponsor Name:Fondazione IRCCS Istituto Nazionale Tumori
    Full Title: A Phase I/II Study of Danusertib in Combination with Romidepsin in Adult Patients with Mature Peripheral T Cell Lymphoma (PTCL)
    Medical condition: (Ph I) Relapsed or refractory Hodgkin (HL) and Non Hodgkin lymphoma (NHL) in patients in the absence, unable ot who have been refused to undergo alternative salvage regimens. (Ph II) Relapsed or r...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10025319 Lymphomas Hodgkin's disease HLGT
    14.1 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    14.1 10005329 - Blood and lymphatic system disorders 10025322 Lymphomas non-Hodgkin's unspecified histology HLGT
    14.1 10005329 - Blood and lymphatic system disorders 10025321 Lymphomas non-Hodgkin's T-cell HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-000051-16 Sponsor Protocol Number: JX594-HEP018 Start Date*: 2012-12-21
    Sponsor Name:Jennerex, Inc
    Full Title: A Phase 2b Randomized Open-Label Trial of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) Plus Best Supportive Care Versus Best Supportive Care in Patients with Advanced Hepatocellular Carcinoma Wh...
    Medical condition: Advanced hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-012807-25 Sponsor Protocol Number: IIL-MCL0208 Start Date*: 2010-01-28
    Sponsor Name:IIL INTERGRUPPO ITALIANO LINFOMI ONLUS
    Full Title: A PHASE III MULTICENTER, RANDOMIZED STUDY WITH LENALIDOMIDE (Revlimid) MAINTENANCE VERSUS OBSERVATION AFTER INTENSIFIED INDUCTION REGIMEN CONTAINING RITUXIMAB FOLLOWED BY HIGH DOSE CHEMOTHERAPY A...
    Medical condition: Mantel cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061275 LLT
    9.1 10061275 LLT
    9.1 10061275 LLT
    9.1 10061275 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed) PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004210-35 Sponsor Protocol Number: ABC-HCC Start Date*: 2021-02-25
    Sponsor Name:Frankfurter Institut für Klinische Krebsforschung IKF GmbH
    Full Title: The ABC-HCC Trial: A Phase IIIb, randomized, multicenter, open-label trial of Atezolizumab plus Bevacizumab versus transarterial Chemoembolization (TACE) in intermediate-stage Hepatocellular carcin...
    Medical condition: intermediate-stage hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049010 Carcinoma hepatocellular LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) AT (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-021590-37 Sponsor Protocol Number: A4061058 Start Date*: 2011-01-03
    Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY10017,USA
    Full Title: A MULTICENTER, GLOBAL, RANDOMIZED, DOUBLE-BLIND STUDY OF AXITINIB PLUS BEST SUPPORTIVE CARE VERSUS PLACEBO PLUS BEST SUPPORTIVE CARE IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA FOLLOWING FAI...
    Medical condition: Hepatocellular carcinoma (HCC)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019829 Hepatocellular carcinoma recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) SK (Completed) GB (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-003202-14 Sponsor Protocol Number: PCYC-1141-CA Start Date*: 2017-04-12
    Sponsor Name:Pharmacyclics LLC
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination wit...
    Medical condition: Follicular lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10029473 Nodular (follicular) lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) CZ (Trial now transitioned) HU (Trial now transitioned) PT (Trial now transitioned) BE (Trial now transitioned) GR (Trial now transitioned) NL (Trial now transitioned) AT (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-004710-16 Sponsor Protocol Number: TPU-S1301 Start Date*: 2005-07-01
    Sponsor Name:Taiho Pharma USA, Inc.
    Full Title: An open label, multicenter, randomized, phase 3 study of S-1 in combination with cisplatin compared against 5-FU in combination with cisplatin in patients with advanced gastric cancer previously un...
    Medical condition: Advanced gastric cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) CZ (Completed) DE (Completed) EE (Completed) BE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-010760-42 Sponsor Protocol Number: 4SC-201-1-2009 Start Date*: 2009-06-19
    Sponsor Name:4SC AG
    Full Title: A proof-of-concept Phase II study to evaluate efficacy, safety and pharmacokinetics of 4SC-201 and the treatment combination of Sorafenib plus 4SC-201 in patients with hepatocellular carcinoma exhi...
    Medical condition: Patients aged ≥ 18, of both gender, with advanced stage hepatocellular carcinoma, BCLC class B (intermediate stage, performance status-ECOG 0, multinodular HCC) or C (advanced stage, performance st...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-001506-25 Sponsor Protocol Number: NN028-1802 Start Date*: Information not available in EudraCT
    Sponsor Name:Novo Nordisk A/S
    Full Title: An open–label Phase 2 Trial of Pegylated Liposomal Doxorubicin and rIL-21 in Ovarian Cancer Patients with Persistent or Progressive Disease after, or Relapse within One Year of, Completion of Stand...
    Medical condition: advanced epithelial Ovarian Cancer stage IIB-IV
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033162 Ovarian epithelial cancer stage II LLT
    9.1 10033163 Ovarian epithelial cancer stage III LLT
    9.1 10033164 Ovarian epithelial cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-005086-41 Sponsor Protocol Number: B1030-101 Start Date*: 2022-12-06
    Sponsor Name:SOTIO Biotech Inc
    Full Title: A First-in-Human, Phase 1/2, Dose Escalation Study of BOXR1030 T cells in Subjects With Advanced GPC3-Positive Solid Tumors.
    Medical condition: Histologically confirmed advanced unresectable or metastatic hepatocellular carcinoma (HCC), squamous cell carcinoma (SCC) of the lung, myxoid/round cell liposarcoma, or Merkel cell carcinoma (MCC)...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077738 Hepatocellular carcinoma metastatic LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025120 Lung squamous cell carcinoma recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073139 Round cell liposarcoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064025 Merkel cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001576-12 Sponsor Protocol Number: SGI-110-02 Start Date*: 2013-07-22
    Sponsor Name:Astex Pharmaceuticals Inc
    Full Title: A Randomized, Controlled, Open-Label, Phase 2 Trial of SGI-110 and Carboplatin in Subjects with Platinum-Resistant Recurrent Ovarian Cancer
    Medical condition: Platinum-Resistant Recurrent Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 11:50:43 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA